For the media
Measuring what matters
Our SomaScan® Platform provides insight into human biology based on measuring thousands of proteins in a single biological sample. Read more
Why measure proteins?
Proteins are the most accurate measure of current health states and future disease risks. Read more
One sample, multiple insights
Proteomics is powering transformational research that discovers life-changing drugs and brings safer and more effective treatments to patients faster. Read more
The predictive promise of proteomics
Proteomics is revolutionizing the continuum of care from improving the accuracy of prognostic and diagnostic testing to uncovering new treatment options for patients through advances in precision medicine. Read more
Latest press releases
SEPTEMBER 19 2023
SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics marke
BOULDER, Colo. and SEOUL, Korea, Sept. 19, 2023 (GLOBE NEWSWIRE) — SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its partnership with DNA Link, an innovator in personalized and precision medicine, to offer the 7,000-plex SomaScan® platform to their customers. DNA Link will be the first SomaLogic authorized site in Korea.
SEPTEMBER 12 2023
SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors
BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) — In a new paper published in Nature’s Scientific Reports, researchers at SomaLogic Inc. studied the value of protein biomarkers in the early detection of cancer and the stratification of cancerous tumors. The research team identified 15 blood proteins shared among all cancer types as well as models to stratify tumor types.
SEPTEMBER 5 2023
SomaLogic expands agreement with Novo Nordisk to 2025
BOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan® proteomics platform in drug research and development.